Integra LifeSciences (IART) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

IART Stock Forecast


Integra LifeSciences stock forecast is as follows: an average price target of $43.00 (represents a 86.96% upside from IART’s last price of $23.00) and a rating consensus of 'Sell', based on 6 wall street analysts offering a 1-year stock forecast.

IART Price Target


The average price target for Integra LifeSciences (IART) is $43.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $20.00. This represents a potential 86.96% upside from IART's last price of $23.00.

IART Analyst Ratings


Sell

According to 6 Wall Street analysts, Integra LifeSciences's rating consensus is 'Sell'. The analyst rating breakdown for IART stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 1 'Hold' (16.67%), 3 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).

Integra LifeSciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2024Ryan ZimmermanBTIG$20.00$17.4314.74%-13.04%
Jul 30, 2024Richard NewitterTruist Financial$26.00$24.595.73%13.04%
Jul 30, 2024Joanne WuenschCitigroup$23.00$25.42-9.52%-
Jul 29, 2024Ryan ZimmermanBTIG$22.00$25.42-13.45%-4.35%
Jul 16, 2024Richard NewitterTruist Financial$32.00$29.847.24%39.13%
May 07, 2024Richard NewitterTruist Financial$25.00$23.148.04%8.70%
May 07, 2024David TurkalyJMP Securities$40.00$23.1472.86%73.91%
May 06, 2024Vik ChopraWells Fargo$25.00$23.148.04%8.70%
Oct 26, 2022Matt O'BrienPiper Sandler$50.00$46.856.72%117.39%
Jul 28, 2022FY22 EPSPiper Sandler$55.00$56.53-2.71%139.13%
Row per page
Go to

The latest Integra LifeSciences stock forecast, released on Oct 07, 2024 by Ryan Zimmerman from BTIG, set a price target of $20.00, which represents a 14.74% increase from the stock price at the time of the forecast ($17.43), and a -13.04% decrease from IART last price ($23.00).

Integra LifeSciences Price Target by Period


1M3M12M
# Anlaysts-18
Avg Price Target-$20.00$26.63
Last Closing Price$23.00$23.00$23.00
Upside/Downside-100.00%-13.04%15.78%

In the current month, the average price target of Integra LifeSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Integra LifeSciences's last price of $23.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024CitigroupSellSellHold
Jul 30, 2024JMP SecuritiesMarket OutperformMarket OutperformHold
Jul 30, 2024CitigroupNeutralSellDowngrade
Jul 29, 2024BTIGSellNegativeDowngrade
Jul 29, 2024BTIG-SellDowngrade
Jul 15, 2024Morgan StanleyUnderweightUnderweightHold
Jul 10, 2024CitigroupNeutralNeutralHold
May 22, 2024CitigroupNeutralNeutralHold
May 07, 2024Wells FargoMarket OutperformMarket OutperformHold
May 07, 2024Truist FinancialUnderperformUnderperformHold
Row per page
Go to

Integra LifeSciences's last stock rating was published by Citigroup on Nov 04, 2024. The company gave IART a "Sell" rating, the same as its previous rate.

Integra LifeSciences Financial Forecast


Integra LifeSciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue--------------$381.27M$380.85M$398.02M$385.19M$397.81M$376.64M$405.52M$386.86M$389.99M$360.07M$388.65M$370.23M$258.67M$354.32M$395.13M$379.10M
Avg Forecast$476.67M$427.80M$451.00M$429.57M$459.54M$410.14M$430.59M$408.54M$445.04M$375.81M$413.07M$363.74M$399.34M$387.22M$374.01M$373.23M$397.92M$378.33M$395.35M$362.41M$404.56M$384.62M$376.11M$349.78M$389.06M$351.65M$243.82M$359.84M$397.52M$376.27M
High Forecast$485.48M$435.71M$459.34M$437.51M$468.04M$417.73M$438.55M$421.20M$447.44M$375.82M$413.07M$364.63M$400.71M$387.22M$380.93M$380.13M$405.28M$378.33M$395.35M$362.41M$404.56M$384.62M$376.11M$349.78M$389.06M$351.65M$243.82M$359.84M$397.52M$376.27M
Low Forecast$466.22M$418.43M$441.12M$420.15M$449.47M$401.16M$421.16M$391.98M$442.67M$375.81M$413.07M$362.85M$397.66M$387.22M$365.82M$365.05M$389.20M$378.33M$395.35M$362.41M$404.56M$384.62M$376.11M$349.78M$389.06M$351.65M$243.82M$359.84M$397.52M$376.27M
# Analysts222211149474946437434744545443
Surprise %--------------1.02%1.02%1.00%1.02%1.01%1.04%1.00%1.01%1.04%1.03%1.00%1.05%1.06%0.98%0.99%1.01%

Integra LifeSciences's average Quarter revenue forecast for Sep 23 based on 4 analysts is $387.22M, with a low forecast of $387.22M, and a high forecast of $387.22M. IART's average Quarter revenue forecast represents a 1.56% increase compared to the company's last Quarter revenue of $381.27M (Jun 23).

Integra LifeSciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211149474946437434744545443
EBITDA--------------$12.50M$44.99M$80.64M$100.43M$93.42M$80.69M$67.99M$93.10M$87.73M$109.42M$82.44M$93.33M$47.01M$58.34M$67.75M$14.05M
Avg Forecast$103.43M$92.83M$97.86M$93.21M$99.71M$89.00M$93.43M$88.65M$96.57M$81.55M$89.63M$89.02M$86.65M$84.02M$81.16M$80.93M$73.89M$60.74M$63.47M$73.57M$64.95M$61.75M$60.38M$86.39M$62.46M$56.46M$39.14M$72.24M$63.82M$60.41M
High Forecast$105.34M$94.54M$99.67M$94.93M$101.56M$90.64M$95.16M$91.40M$97.09M$81.55M$89.63M$106.83M$86.95M$84.02M$82.66M$97.12M$88.66M$60.74M$63.47M$88.29M$64.95M$61.75M$60.38M$103.66M$62.46M$56.46M$39.14M$86.68M$63.82M$60.41M
Low Forecast$101.16M$90.79M$95.72M$91.17M$97.53M$87.05M$91.39M$85.05M$96.05M$81.55M$89.63M$71.22M$86.29M$84.02M$79.38M$64.75M$59.11M$60.74M$63.47M$58.86M$64.95M$61.75M$60.38M$69.11M$62.46M$56.46M$39.14M$57.79M$63.82M$60.41M
Surprise %--------------0.15%0.56%1.09%1.65%1.47%1.10%1.05%1.51%1.45%1.27%1.32%1.65%1.20%0.81%1.06%0.23%

4 analysts predict IART's average Quarter EBITDA for Sep 23 to be $84.02M, with a high of $84.02M and a low of $84.02M. This is 571.96% upper than Integra LifeSciences's previous annual EBITDA (Jun 23) of $12.50M.

Integra LifeSciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211149474946437434744545443
Net Income--------------$4.18M$24.23M$52.95M$49.91M$44.79M$32.90M$45.38M$43.23M$35.07M$45.39M$92.74M$32.34M$-369.00K$9.18M$15.32M$-27.61M
Avg Forecast$66.26M$51.98M$50.97M$47.14M$61.46M$42.39M$45.33M$43.31M$65.29M$29.82M$47.66M$36.30M$69.03M$59.50M$43.52M$33.00M$49.32M$55.75M$61.87M$30.00M$65.08M$56.08M$50.99M$35.84M$56.73M$42.01M$6.95M$11.37M$51.67M$50.65M
High Forecast$67.85M$53.23M$52.19M$48.28M$62.94M$43.41M$46.42M$45.67M$66.82M$29.82M$47.68M$43.56M$70.69M$59.52M$44.57M$39.60M$59.19M$55.75M$61.87M$36.00M$65.08M$56.08M$50.99M$43.00M$56.73M$42.01M$6.95M$13.64M$51.67M$50.65M
Low Forecast$64.37M$50.50M$49.51M$45.80M$59.71M$41.18M$44.04M$40.16M$64.52M$29.82M$47.65M$29.04M$68.27M$59.49M$42.28M$26.40M$39.46M$55.75M$61.87M$24.00M$65.08M$56.08M$50.99M$28.67M$56.73M$42.01M$6.95M$9.09M$51.67M$50.65M
Surprise %--------------0.10%0.73%1.07%0.90%0.72%1.10%0.70%0.77%0.69%1.27%1.63%0.77%-0.05%0.81%0.30%-0.55%

Integra LifeSciences's average Quarter net income forecast for Sep 23 is $59.50M, with a range of $59.49M to $59.52M. IART's average Quarter net income forecast represents a 1322.18% increase compared to the company's last Quarter net income of $4.18M (Jun 23).

Integra LifeSciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211149474946437434744545443
SG&A--------------$164.91M$166.66M$151.92M$143.82M$160.65M$159.93M$162.25M$156.01M$162.55M$156.63M$162.39M$150.08M$116.11M$165.95M$174.25M$173.10M
Avg Forecast$198.28M$177.95M$187.60M$178.69M$191.15M$170.61M$179.11M$169.94M$185.12M$156.33M$171.82M$176.44M$166.11M$161.07M$155.58M$160.40M$176.32M$158.30M$165.42M$145.81M$169.28M$160.94M$157.37M$123.66M$162.79M$147.14M$102.02M$205.46M$166.33M$157.44M
High Forecast$201.95M$181.24M$191.07M$181.99M$194.69M$173.76M$182.42M$175.21M$186.12M$156.33M$171.82M$211.72M$166.68M$161.07M$158.45M$192.48M$211.59M$158.30M$165.42M$174.98M$169.28M$160.94M$157.37M$148.39M$162.79M$147.14M$102.02M$246.56M$166.33M$157.44M
Low Forecast$193.93M$174.05M$183.49M$174.77M$186.97M$166.87M$175.19M$163.05M$184.14M$156.32M$171.82M$141.15M$165.42M$161.07M$152.17M$128.32M$141.06M$158.30M$165.42M$116.65M$169.28M$160.94M$157.37M$98.93M$162.79M$147.14M$102.02M$164.37M$166.33M$157.44M
Surprise %--------------1.06%1.04%0.86%0.91%0.97%1.10%0.96%0.97%1.03%1.27%1.00%1.02%1.14%0.81%1.05%1.10%

Integra LifeSciences's average Quarter SG&A projection for Sep 23 is $161.07M, based on 4 Wall Street analysts, with a range of $161.07M to $161.07M. The forecast indicates a -2.33% fall compared to IART last annual SG&A of $164.91M (Jun 23).

Integra LifeSciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211149474946437434744545443
EPS--------------$0.05$0.30$0.63$0.60$0.54$0.39$0.54$0.51$0.41$0.54$1.10$0.38$-0.00$0.11$0.18$-0.32
Avg Forecast$0.87$0.68$0.67$0.62$0.80$0.55$0.59$0.57$0.85$0.39$0.62$0.55$0.90$0.78$0.57$0.74$0.90$0.72$0.80$0.68$0.84$0.72$0.66$0.57$0.73$0.54$0.09$0.62$0.67$0.65
High Forecast$0.89$0.70$0.68$0.63$0.82$0.57$0.61$0.60$0.87$0.39$0.62$0.55$0.92$0.78$0.58$0.76$0.93$0.72$0.80$0.68$0.84$0.72$0.66$0.57$0.73$0.54$0.09$0.62$0.67$0.65
Low Forecast$0.84$0.66$0.65$0.60$0.78$0.54$0.58$0.53$0.84$0.39$0.62$0.55$0.89$0.78$0.55$0.72$0.88$0.72$0.80$0.68$0.84$0.72$0.66$0.57$0.73$0.54$0.09$0.62$0.67$0.65
Surprise %--------------0.09%0.41%0.70%0.83%0.68%0.57%0.64%0.70%0.63%0.95%1.50%0.71%-0.05%0.18%0.27%-0.49%

According to 4 Wall Street analysts, Integra LifeSciences's projected average Quarter EPS for Sep 23 is $0.78, with a low estimate of $0.78 and a high estimate of $0.78. This represents a 1405.53% increase compared to IART previous annual EPS of $0.05 (Jun 23).

Integra LifeSciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IARTIntegra LifeSciences$23.00$43.0086.96%Sell
CNMDCONMED$71.71$96.0033.87%Buy
HAEHaemonetics$85.43$108.2526.71%Buy
ICUIICU Medical$168.84$172.001.87%Buy
MMSIMerit Medical Systems$105.03$100.78-4.05%Buy

IART Forecast FAQ


Is Integra LifeSciences a good buy?

No, according to 6 Wall Street analysts, Integra LifeSciences (IART) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of IART's total ratings.

What is IART's price target?

Integra LifeSciences (IART) average price target is $43 with a range of $20 to $86, implying a 86.96% from its last price of $23. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Integra LifeSciences stock go up soon?

According to Wall Street analysts' prediction for IART stock, the company can go up by 86.96% (from the last price of $23 to the average price target of $43), up by 273.91% based on the highest stock price target, and down by -13.04% based on the lowest stock price target.

Can Integra LifeSciences stock reach $30?

IART's average twelve months analyst stock price target of $43 supports the claim that Integra LifeSciences can reach $30 in the near future.

What are Integra LifeSciences's analysts' financial forecasts?

Integra LifeSciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.71B (high $1.75B, low $1.66B), average EBITDA is $370.79M (high $378.76M, low $361.02M), average net income is $192.49M (high $198.44M, low $185.09M), average SG&A $710.81M (high $726.08M, low $692.07M), and average EPS is $2.52 (high $2.6, low $2.42). IART's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.79B (high $1.82B, low $1.75B), average EBITDA is $387.33M (high $394.49M, low $378.84M), average net income is $216.35M (high $221.55M, low $210.19M), average SG&A $742.52M (high $756.25M, low $726.25M), and average EPS is $2.83 (high $2.9, low $2.75).

Did the IART's actual financial results beat the analysts' financial forecasts?

Based on Integra LifeSciences's last annual report (Dec 2022), the company's revenue was $1.56B, beating the average analysts forecast of $1.53B by 1.54%. Apple's EBITDA was $276.73M, beating the average prediction of $271.67M by 1.86%. The company's net income was $180.55M, missing the average estimation of $196.94M by -8.32%. Apple's SG&A was $616.32M, missing the average forecast of $645.87M by -4.58%. Lastly, the company's EPS was $2.18, missing the average prediction of $3.11 by -29.82%. In terms of the last quarterly report (Jun 2023), Integra LifeSciences's revenue was $381.27M, beating the average analysts' forecast of $374.01M by 1.94%. The company's EBITDA was $12.5M, missing the average prediction of $81.16M by -84.59%. Integra LifeSciences's net income was $4.18M, missing the average estimation of $43.52M by -90.39%. The company's SG&A was $164.91M, beating the average forecast of $155.58M by 6.00%. Lastly, the company's EPS was $0.0517, missing the average prediction of $0.569 by -90.92%